 ESSA Pharma Inc. ESSA, or the Company Nasdaq: EPIX TSX-V: EPI, a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the pricing of an underwritten public offering of 7,100,000 common shares at a public offering price of US6.00 per share, before underwriting discounts, for an aggregate offering of approximately US42.6 million the Offering. ESSA has granted the underwriters a 30-day option to purchase, in whole or in part, up to an additional 1,065,000 shares of its common shares the Option. The proceeds to ESSA from the Offering are expected to be approximately US39.0 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the Option. ESSA intends to use the net proceeds of the Offering for pre-clinical and clinical activities, chemistry, manufacturing and controls, research and development, as well as working capital and general corporate purposes. All common shares to be sold in the Offering will be offered by ESSA. 